January 29, 2023

Volume XIII, Number 29

Zan Newkirk

Alexander (Zan) Newkirk’s practice encompasses patent litigation, prosecution, and client counseling in the chemical, pharmaceutical, and medical device areas. He has industry experience with pulmonary and nasal medical devices, drug formulation, and vaccine formulation development.

Zan’s litigation experience covers various aspects of trial preparation, including discovery and regular pre-trial activities. He has worked on ANDA (Abbreviated New Drug Application) litigation.

Prior to law school, Zan interned at Novavax, a vaccine development company, where he analyzed influenza and RSV (Respiratory Syncytial Virus) vaccines using laboratory techniques such as DLS (Dynamic Light Scattering) particle sizing, ELISA (Enzyme-Linked Immunosorbent Assay), and SDS-PAGE (Sodium Dodecyl Sulfate - Polyacrylamide Gel Electrophoresis). Shortly thereafter, he began work at Catalent, a drug development company, where he analyzed inhaler and nebulizer products using HPLC (High Performance Liquid Chromatography) and GC/MS (Gas Chromatography/Mass Spectrometry).

In law school, Zan served on the executive board of the University of North Carolina at Chapel Hill’s Intellectual Property Law Association and wrote for the North Carolina Journal of Law and Technology.

Pro bono work is a vital part of Zan’s practice. Cases he has worked on include juvenile resentencing and asylum cases.

Articles in the National Law Review database by Zan Newkirk